Search results for "EPA"

showing 10 items of 8995 documents

Rab33B Controls Hepatitis B Virus Assembly by Regulating Core Membrane Association and Nucleocapsid Processing

2017

Many viruses take advantage of cellular trafficking machineries to assemble and release new infectious particles. Using RNA interference (RNAi), we demonstrate that the Golgi/autophagosome-associated Rab33B is required for hepatitis B virus (HBV) propagation in hepatoma cell lines. While Rab33B is dispensable for the secretion of HBV subviral envelope particles, its knockdown reduced the virus yield to 20% and inhibited nucleocapsid (NC) formation and/or NC trafficking. The overexpression of a GDP-restricted Rab33B mutant phenocopied the effect of deficit Rab33B, indicating that Rab33B-specific effector proteins may be involved. Moreover, we found that HBV replication enhanced Rab33B expres…

0301 basic medicineHepatitis B virusBiologymedicine.disease_causeVirusArticleCell LineCell membraneRab33B03 medical and health sciencesnucleocapsid assemblyTranscription (biology)RNA interferenceVirologymedicineHumansSecretionNucleocapsidcore/capsid membrane associationHepatitis B virus030102 biochemistry & molecular biologyEffectorVirus AssemblyCell MembraneVirologyHepatitis B Core Antigenshepatitis B virus; Rab GTPase; Rab33B; core/capsid membrane association; nucleocapsid assembly; virus traffickingTransport proteinProtein Transport030104 developmental biologyInfectious Diseasesmedicine.anatomical_structurevirus traffickingrab GTP-Binding ProteinsHost-Pathogen InteractionsHepatocytesRab GTPaseViruses; Volume 9; Issue 6; Pages: 157
researchProduct

Novel strategies in vaccine design: can nanocapsules help prevent and treat hepatitis B?

2017

0301 basic medicineHepatitis B virusBiomedical EngineeringMedicine (miscellaneous)BioengineeringDevelopmentmedicine.disease_causeHepatitis b surface antigenNanocapsules03 medical and health sciences0302 clinical medicineNanocapsulesmedicineHumansGeneral Materials ScienceHepatitis B Vaccines030212 general & internal medicineHepatitis B virusHepatitis B Surface Antigensbusiness.industryHepatitis Bmedicine.diseaseHepatitis BVirologyVaccination030104 developmental biologyImmunizationImmunizationbusinessNanomedicine (London, England)
researchProduct

The immunoglobulin γ marker 17 allotype and KIR/HLA genes prevent the development of chronic hepatitis B in humans

2020

Hepatitis B virus (HBV) infection causes a self-limiting disease in most individuals. However, < 10% of infected subjects develop a chronic disease. Genetic host variability of polymorphic genes at the interface of innate and acquired immunity, such as killer immunoglobulin-like receptors (KIR), their human leucocyte antigen (HLA) and IgG allotypes (GM), could explain this different clinical picture. We previously showed a protective role of the KIR2DL3 gene for the development of chronic hepatitis B (CHB), and a detrimental role of the KIR ligand groups, HLA-A-Bw4 and HLA-C2. We have expanded the previous analysis genotyping patients for GM23 and GM3/17 allotypes. The comparison of the …

0301 basic medicineHepatitis B virusKIR LigandImmunologyhepatitis B viruHuman leukocyte antigenHLA-C Antigensmedicine.disease_causeRisk Assessment03 medical and health sciences0302 clinical medicineHepatitis B ChronicGene FrequencyImmunoglobulin Gm AllotypesRisk Factorskiller immunoglobulin-like receptorImmunology and AllergyMedicineHumansGenetic Predisposition to DiseaseGenotypingHepatitis B virusSettore MED/04 - Patologia Generalebiologybusiness.industryOriginal ArticlesProtective FactorsAcquired immune systemAllotypeγ marker030104 developmental biologyPhenotypeHLA-B AntigensReceptors KIR2DL3Case-Control StudiesImmunologyHost-Pathogen Interactionsbiology.proteinGene polymorphismAntibodyhepatitis B virus; human leucocyte antigen; killer immunoglobulin-like receptor; ? markerbusiness030215 immunologyhuman leucocyte antigen
researchProduct

Hepatitis B Virus Exploits ERGIC-53 in Conjunction with COPII to Exit Cells.

2020

Several decades after its discovery, the hepatitis B virus (HBV) still displays one of the most successful pathogens in human populations worldwide. The identification and characterization of interactions between cellular and pathogenic components are essential for the development of antiviral treatments. Due to its small-sized genome, HBV highly depends on cellular functions to produce and export progeny particles. Deploying biochemical-silencing methods and molecular interaction studies in HBV-expressing liver cells, we herein identified the cellular ERGIC-53, a high-mannose-specific lectin, and distinct components of the endoplasmic reticulum (ER) export machinery COPII as crucial factor…

0301 basic medicineHepatitis B virusSec24AEndosomeHBV assemblyVesicular Transport ProteinsN-glycosylationBiologymedicine.disease_causeEndoplasmic ReticulumTransfectionGenomeESCRTArticle03 medical and health sciencesN-linked glycosylationViral life cycleCell Line TumormedicineHBVHumansCOPIICOPIIlcsh:QH301-705.5Hepatitis B virus030102 biochemistry & molecular biologyEndosomal Sorting Complexes Required for TransportEndoplasmic reticulumVirionMembrane ProteinsGeneral MedicineHepatitis BHBV egressERGIC-53Cell biologyProtein Transport030104 developmental biologyMannose-Binding Lectinslcsh:Biology (General)HepatocytesLMAN-1COP-Coated VesiclesCells
researchProduct

APOBEC3-mediated restriction of RNA virus replication

2018

AbstractAPOBEC3 family members are cytidine deaminases with roles in intrinsic responses to infection by retroviruses and retrotransposons, and in the control of other DNA viruses, such as herpesviruses, parvoviruses and hepatitis B virus. Although effects of APOBEC3 members on viral DNA have been demonstrated, it is not known whether they edit RNA genomes through cytidine deamination. Here, we investigated APOBEC3-mediated restriction of Coronaviridae. In experiments in vitro, three human APOBEC3 proteins (A3C, A3F and A3H) inhibited HCoV-NL63 infection and limited production of progeny virus, but did not cause hypermutation of the coronaviral genome. APOBEC3-mediated restriction was parti…

0301 basic medicineHepatitis B virusviruseslcsh:MedicineGenome Viralmedicine.disease_causeVirus ReplicationVirusArticleCell LineCytosine Deaminase03 medical and health scienceschemistry.chemical_compoundCytidine deaminationCytidine DeaminasemedicineCoronaviridaeHumansRNA VirusesAPOBEC Deaminaseslcsh:ScienceCoronavirusMultidisciplinarybiology630 Agriculturelcsh:RDNA VirusesRNARNA virusbiochemical phenomena metabolism and nutritionbiology.organism_classificationVirology3. Good health030104 developmental biologyNucleoproteinschemistryViral replicationRNA570 Life sciences; biologylcsh:QDNA
researchProduct

Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy

2021

Background & Aims There are limited data on patients with chronic HCV infection in whom combination voxilaprevir (VOX), velpatasvir (VEL), sofosbuvir (SOF) retreatment fails. Thus, we aimed to assess treatment failure and rescue treatment options in these patients. Methods Samples from 40 patients with HCV genotypes (GT) 1-4 in whom VOX/VEL/SOF retreatment failed were collected within the European Resistance Study Group. Population-based resistance analyses were conducted and clinical parameters and retreatment efficacies were evaluated retrospectively in 22 patients. Results Most VOX/VEL/SOF failure patients were infected with HCV GT3a (n = 18, 45%) or GT1a (n = 11, 28%) and had cirrhosis …

0301 basic medicineHepatitis C Virusmedicine.medical_specialtySofosbuvirVoxilaprevirPopulationresistance-associated substitutionsDirect-acting antiviralVoxilaprevir/velpatasvir/sofosbuvir.GastroenterologySettore MED/07Telaprevir03 medical and health scienceschemistry.chemical_compound0302 clinical medicineVoxilaprevir/Velpatasvir/SofosbuvirInternal medicineBoceprevirRescue therapymedicineResistance-associated substitutioneducationdirect-acting antiviralsDAAeducation.field_of_studyHepatologybusiness.industryvirus diseasesGlecaprevirDAA; HCV; Hepatitis C Virus; Voxilaprevir/Velpatasvir/Sofosbuvir; direct-acting antivirals; rescue therapy; resistance-associated substitutionsdigestive system diseasesPibrentasvirRegimen030104 developmental biologychemistryHCV030211 gastroenterology & hepatologyHepatitis C virubusinessmedicine.drugJournal of Hepatology
researchProduct

Molecular targets in inhibition of hepatitis C virus replication

1997

Hepatitis C virus (HCV) is the major cause of transfusion-associated hepatitis and accounts for a significant proportion of hepatitis cases worldwide. Most, if not all, infections become persistent and about 60% of cases develop chronic liver disease with various outcomes ranging from an asymptomatic carrier state to chronic active hepatitis and liver cirrhosis, which is strongly associated with the development of hepatocellular carcinoma. Since the initial cloning of the viral genome in 1989, our knowledge of the molecular biology of HCV has increased rapidly and led to the identification of several potential targets for antiviral intervention. In contrast, the low replication of the virus…

0301 basic medicineHepatitisCirrhosisbiologyHepatitis C virus030106 microbiologyGeneral Medicinebiology.organism_classificationmedicine.diseaseChronic liver diseasemedicine.disease_cause01 natural sciencesVirologyVirus0104 chemical sciences010404 medicinal & biomolecular chemistry03 medical and health sciencesFlaviviridaeDrug developmentHepatocellular carcinomaImmunologymedicine
researchProduct

Interferon lambda 4 rs368234815 TT>δG variant is associated with liver damage in patients with nonalcoholic fatty liver disease

2017

Background and Aims: The IFNL3/4 locus influencing innate immunity regulation has been associated with the severity of hepatitis and fibrosis progression during chronic hepatitis C infection, while contrasting results were reported in NAFLD. In this study, we examined whether rs12979860 and the linked causal rs368234815 variant encoding for the alternative IFNL4 protein variant are associated with liver fibrosis and damage in a large multicenter cohort of patients at risk of NASH. To clarify the mechanism, we also evaluated the impact on interferon-stimulated gene (ISG) hepatic expression in a subset of patients. Methods: We considered 946 consecutive Italian individuals at risk of NASH wit…

0301 basic medicineHepatitismedicine.medical_specialtyNAFLD NASH IFNL4Hepatologybusiness.industryLocus (genetics)medicine.diseaseGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicineFibrosisInternal medicineNonalcoholic fatty liver diseaseCohortGenotypemedicine030211 gastroenterology & hepatologyAllelebusinessProspective cohort studyHepatology
researchProduct

Molecular bases of the poor response of liver cancer to chemotherapy

2018

Summary A characteristic shared by most frequent types of primary liver cancer, i.e., hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) in adults, and in a lesser extent hepatoblastoma (HB) mainly in children, is their high refractoriness to chemotherapy. This is the result of synergic interactions among complex and diverse mechanisms of chemoresistance (MOC) in which more than 100 genes are involved. Pharmacological treatment, although it can be initially effective, frequently stimulates the expression of MOC genes, which results in the relapse of the tumor, usually with a more aggressive and less chemosensitive phenotype. Identification of the MOC genetic signature accounting fo…

0301 basic medicineHepatoblastomaCarcinoma HepatocellularGenetic enhancementmedicine.medical_treatmentCholangiocarcinoma03 medical and health sciences0302 clinical medicineHumansMedicinecholangiocarcinoma; hepatoblastoma; hepatocellular carcinoma; multidrug resistance; targeted therapies; hepatology; gastroenterologyChemotherapyHepatologybusiness.industryLiver NeoplasmsGastroenterologymedicine.diseasePhenotypeResistome030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaCancer cellCancer researchbusinessLiver cancerClinics and Research in Hepatology and Gastroenterology
researchProduct

Novel deletion in 11p15.5 imprinting center region 1 in a patient with Beckwith-Wiedemann syndrome provides insight into distal enhancer regulation a…

2016

Background Beckwith–Wiedemann syndrome (BWS) is an early-onset overgrowth disorder with a high risk for embryonal tumors. It is mainly caused by dysregulation of imprinted genes on chromosome 11p15.5; however, the driving forces in the development of tumors are not fully understood. Procedure We report on a female patient presenting with macrosomia, macroglossia, organomegaly and extensive bilateral nephroblastomatosis. Adjuvant chemotherapy was initiated; however, the patient developed hepatoblastoma and Wilms tumor at 5 and 12 months of age, respectively. Subsequent radiofrequency ablation of the liver tumor and partial nephrectomy followed by consolidation therapy achieved complete remis…

0301 basic medicineHepatoblastomaPathologymedicine.medical_specialtyBeckwith-Wiedemann SyndromeBeckwith–Wiedemann syndrome030105 genetics & hereditymedicine.disease_cause03 medical and health sciencesGenomic ImprintingInsulin-Like Growth Factor IIMacroglossiaMedicineHumansImprinting (psychology)NephroblastomatosisSequence Deletionbusiness.industryChromosomes Human Pair 11Infant NewbornWilms' tumorHematologyDNA Methylationmedicine.diseasePrognosis030104 developmental biologyCell Transformation NeoplasticPhenotypeOncologyPediatrics Perinatology and Child HealthCancer researchFemalemedicine.symptombusinessGenomic imprintingCarcinogenesisPediatric bloodcancer
researchProduct